Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2017

Oct 30, 2017

30718_dirs_2017-10-30_0a4da66c-93d2-4fa5-baf2-8b7cc04b18f3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2017-10-26

Reporting Person: Kummeth Charles R. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-10-26 Common Stock A 14194.00 $0.00 Acquired 84472.00 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-10-26 Restricted Stock Unit $ A 21291.00 Acquired Common Stock (21291.00) Direct
2017-10-26 Stock Options (Right to buy) $125.05 A 117342.00 Acquired 2024-08-09 Common Stock (117342.00) Direct
2017-10-26 Stock Options (Right to buy) $125.05 A 78228.00 Acquired 2024-08-09 Common Stock (78228.00) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Restricted Stock Unit $ Common Stock (17283.00) 17283.00 Direct
Restricted Stock Unit $ Common Stock (24979.00) 24979.00 Direct
Stock Option (Right to Buy) $108.49 2022-08-07 Common Stock (79517.00) 79517.00 Direct
Stock Option (Right to Buy) $108.49 2022-08-07 Common Stock (119275.00) 119275.00 Direct
Stock Option (Right to Buy) $106.59 2023-08-18 Common Stock (102779.00) 102779.00 Direct
Stock Option (Right to Buy) $106.59 2023-08-18 Common Stock (154169.00) 154169.00 Direct
Stock Option (Right to Buy) $86.25 2021-04-01 Common Stock (46316.00) 46316.00 Direct
Stock Option (Right to Buy) $67.46 2020-04-01 Common Stock (65000.00) 65000.00 Direct
Stock Option (Right to Buy) $67.46 2020-04-01 Common Stock (50000.00) 50000.00 Direct
Stock Options (Right to buy) $94.35 2021-08-12 Common Stock (66849.00) 66849.00 Direct

Footnotes

F1: Includes (i) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; (ii) 3,841 shares for which the risks of forfeiture will lapse on August 7, 2018; and (iii) 11,102 shares for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2018 and August 18, 2019; and (iv) 4,731 shares each which risks of forfeiture will lapse on August 9, 2018 and August 9, 2019; and (v) 4,732 shares for which risks of forfeiture will lapse on August 9, 2020.

F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F3: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F4: Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021

F5: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F7: 19,879 shares vest on each of August 7, 2016, August 7, 2017 and August 7, 2018 and 19,880 shares vest on August 7, 2019.

F8: Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.

F9: The option will vest pursuant to the following schedule: 5,790 shares on October 1, 2014, 965 shares on the first day of the month for the period beginning November 1, 2014 and ending March 1, 2018, and 961 shares on April 1, 2018.

F10: Fully exercisable